Sonnet BioTherapeutics (SONN) announced the appointment of Stephen McAndrew, Ph.D., as Chief Business Officer, effective February 17, 2025. During the course of his tenure at Sonnet, Dr. McAndrew has served as Vice President and then Senior Vice President, Business Development, and has been responsible for developing and leading the Company’s partnering strategy, establishing and managing current collaborative research partnerships, and managing the global intellectual property portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SONN:
- Sonnet BioTherapeutics reports Q1 EPS ($1.56) vs ($2.46) last year
- Sonnet BioTherapeutics appoints McAndrew as CBO, Griffith as CFO
- Sonnet BioTherapeutics Secures EU Patent for FHAB Technology
- Sonnet BioTherapeutics further expands global IP portfolio
- Sonnet BioTherapeutics files to sell 2M shares of common stock for holders